🇺🇸 FDA
Patent

US 12129471

Materials and methods for treatment of human genetic diseases including hemoglobinopathies

granted A61KA61K48/005A61P

Quick answer

US patent 12129471 (Materials and methods for treatment of human genetic diseases including hemoglobinopathies) held by Vertex Pharmaceuticals Incorporated expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K48/005, A61P, A61P7/06